CAMK1D and diabetes mellitus: A study using mice as a model showed that highly selective calmodulin-dependent kinase inhibitors, such as CaMK1 selective inhibitors, can restore insulin sensitivity, confirming CaMK1D as a target for diabetes treatment (86).